The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 26, 2019

Filed:

Dec. 08, 2014
Applicant:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Inventors:

Robert H. Pierce, San Francisco, CA (US);

Jennifer H. Yearley, Palo Alto, CA (US);

Scott P. Turner, Sunnyvale, CA (US);

Belma Dogdas, Secaucus, NJ (US);

Ansuman Bagchi, Plainsboro, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G06T 7/00 (2017.01); G06T 7/11 (2017.01); G06T 7/41 (2017.01); G06T 7/90 (2017.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); G06F 19/00 (2018.01); G01N 33/574 (2006.01); C12Q 1/6886 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57492 (2013.01); C07K 16/2818 (2013.01); C12Q 1/6886 (2013.01); G01N 33/574 (2013.01); G06F 19/00 (2013.01); G06F 19/34 (2013.01); G06T 7/0012 (2013.01); G06T 7/11 (2017.01); G06T 7/41 (2017.01); G06T 7/90 (2017.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/70521 (2013.01); G01N 2333/70532 (2013.01); G01N 2800/52 (2013.01); G06T 2207/10024 (2013.01); G06T 2207/10056 (2013.01); G06T 2207/10064 (2013.01); G06T 2207/20021 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30096 (2013.01); G06T 2207/30204 (2013.01);
Abstract

The present disclosure describes an IHC assay for detecting and quantifying spatially proximal pairs of PD-1-expressing cells (PD-1+ cells) and PD-Ligand-expressing cells (PD-L+ cells) in tumor tissue, and the use of the assay to generate proximity biomarkers that are predictive of which cancer patients are most likely to benefit from treatment with a PD-1 antagonist. The disclosure also provides methods for testing tumor samples for the proximity biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.


Find Patent Forward Citations

Loading…